WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: Asthma, Spirometry PEFR Assessment Administration of Bronchodilator Results in Increase in FEV1, Inflammatory cells Results in decrease of Eosinophils, Bind to and inhibit the M3 receptor causes reduced tonus of vagus, Local Cromone Usage Start 1-2 weeks before exposure, Allergic rhinits Symptoms Congestion, Inflammatory cells Results in decrease of Mast cells, Structural Cells Causing Decreases in Mucus secretions, Asthma Types Intrinsic (non atopic), Bronchodilators Muscarinic Antagonists Bind to and inhibit the M3 receptor, Local Cromone Symptom improvement Rhinorrhea, Second Gen. H1 Antihistamine Symptom improvement Nasal pruritus, History Classifications Chronic, Asthma Pharmacotherapy Bronchodilators, Intranasal Decongestant Usage Limit to 5-7 days, Mast cell Stabilizer Prevents Release of histamine and other allergic mediators, Asthma symptoms Wheezing, Asthma Pathophysiology Immediate/Early Phase, Chronic Symptoms More than 4 days AND more than 4 weeks, Clinical Diagnosis Indications Other Manifestation Such as Eczema, Intra-nasal steroids Symptom improvement Rhinorrhea